N-hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase.
Two series of compounds (1 and 2) having structural features of the dual COX/5-LO inhibitor tepoxalin and the 5-LO inhibitor ABT-761 were prepared. Many of these hybrid compounds are potent COX and 5-LO inhibitors; two compounds (1a and 2t) inhibit eicosanoid biosynthesis in an ex vivo assay.
Connolly
P J
PJ
The R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ 08869, USA.
Wetter
S K
SK
Beers
K N
KN
Hamel
S C
SC
Chen
R H
RH
Wachter
M P
MP
Ansell
J
J
Singer
M M
MM
Steber
M
M
Ritchie
D M
DM
Argentieri
D C
DC
D000818:Animals; D016861:Cyclooxygenase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D004285:Dogs; D006877:Hydroxamic Acids / Q000737:chemistry / Q000494:pharmacology*; D006918:Hydroxyurea / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D066298:In Vitro Techniques; D016859:Lipoxygenase Inhibitors / Q000737:chemistry / Q000494:pharmacology*
D016861:Cyclooxygenase Inhibitors; D006877:Hydroxamic Acids; D016859:Lipoxygenase Inhibitors; C096921:atreleuton; D006918:Hydroxyurea